06-reference/research

glp1 discontinuation cohort past 18 months

2026-10-12·research-brief·source: deep-research·by Ray Data Co (deep-research synthesis)
investinglly-longevity-v1virta-healthglp1-discontinuationevidence-gap

There is no published evidence past 18 months, and the "peer-reviewed 18-month" figure in our own vault was a misread

The question

"What happens to the GLP-1-discontinuation subgroup past 18 months? That cohort, not the 2015-16 DRCP cohort, is the cleanest test of behavioral substitution — the DRCP enrollment predates widespread GLP-1 use entirely."

Carried forward unresolved through two prior briefs. The question's framing is correct: the Diabetes Research and Clinical Practice continuous-care cohort enrolled August 2015 to May 2016 and cannot test substitution. The deprescription cohort can. The answer is that the deprescription cohort stops at 12 months, and the "18 months" that made this question seem answerable does not refer to post-discontinuation follow-up at all.

What we already know (from the vault)

What the web says

The behavioral-substitution test (discontinuation INTO a program) — exactly one peer-reviewed study exists, and it stops at 12 months.

Pure discontinuation (no structured program) — the randomized ceiling is also 12 months off-drug.

Real-world claims and records cohorts — nothing clean past 12 months either.

Convergences and contradictions

Synthesis for RDCO

The finding is a gap, and it should be written into the thesis as a gap. The longest credible follow-up on a deprescribing-into-program cohort is 12 months, not 18, and it is one Virta-funded, non-randomized, responder-selected study of 154 patients that is 68.1% composed (my arithmetic: 43.5 + 17.5 + 7.1) of dulaglutide, liraglutide and exenatide users with zero tirzepatide exposure. The behavioral-substitution bear vector against [[2026-05-21-lilly-glp1-longevity-thesis]] therefore cannot be strengthened or refuted by durability data, because the durability data does not exist at the horizon that would matter. Three briefs in this thread have now tried to resolve substitution durability from the Virta evidence base. The correct conclusion is that this line of inquiry is exhausted until someone publishes a longer cohort, and continuing to mine it is spending research budget on a question the literature cannot currently answer.

The single most bearish datum in the literature is in this paper, and it is weaker than it looks. At 12 months, 64.8% of the deprescribed cohort held HbA1c below 6.5% versus 64.1% of those who stayed on the drug. Continuing the GLP-1 bought essentially nothing. Taken at face value that is the substitution thesis in miniature. But both cohorts entered at 100% below 6.5% by inclusion criteria, so 35.2 percentage points of the deprescribed cohort lost glycemic target within a single year (my arithmetic: 100 − 64.8), with the mean drifting 6.0% to 6.2%. The honest read is that both arms were decaying in parallel, and the study is better described as "in glycemic responders on older GLP-1 RAs, the drug was no longer doing marginal work" than as "nutrition therapy replaces the drug." Generalizing it to a tirzepatide or retatrutide patient who lost 22-30% of body weight is an extrapolation across drug classes that the authors themselves decline to make.

For the Lilly position this is mildly supportive, for an unsatisfying reason: the test that would threaten the thesis has not been run. Lilly's franchise economics rest on tirzepatide and, prospectively, retatrutide. The only published behavioral-off-ramp evidence covers a drug mix Lilly largely does not sell into the obesity market, in a type 2 diabetes population at body mass index 35.7, selected for having already achieved target on diet. Meanwhile the randomized withdrawal evidence that does cover the modern agents, SURMOUNT-4 most directly, shows substantial regain and preserves the chronic-use rationale. Net effect on the thesis: no change to the "complement, not substitute" framing that [[2026-05-25-virta-health-5yr-cohort-reversal-durability]] and [[2026-07-30-virta-drcp-5yr-itt-remission-rate]] arrived at. The one thing to add to the thesis file is an explicit evidence-ceiling line, so a future reader does not re-open this: no published post-GLP-1-discontinuation cohort, with or without a behavioral program, reports outcomes beyond 12 months as of 2026-10-12.

One reusable methodological lesson, consistent with the pattern this thread keeps finding. The 2026-07-30 brief caught completer figures laundered as intent-to-treat inside a peer-reviewed discussion section. This brief catches a duration-of-care figure laundered into a follow-up duration across an interview, a vault note, and three downstream briefs. In both cases the correct figure was in the same document, and in both cases the error survived because a number was carried forward without its unit of measurement. Any duration, denominator or percentage entering the vault from a spoken source should be stamped with what it is measuring before it is cited twice.

Why this is in the vault

This closes the last open follow-up of [[2026-10-11-virta-drcp-68-unapproached-participants-denominator]] and retires the behavioral-substitution durability line of the [[2026-05-21-lilly-glp1-longevity-thesis]] bear case as unanswerable from published data, while correcting a factual error ("peer-reviewed 18-month post-discontinuation data") that originated in [[2026-05-22-tim-ferriss-sami-inkinen-virta-t2d-rowing]] and propagated through three research briefs unchallenged.

Open follow-ups

Related

Sources

Primary, read in full this run:

Company-published, used only to establish evidence tier and duration claims:

Secondary, characterized from search summaries rather than read (flagged):

Own arithmetic (labelled, not from any source):